FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3039660397> ?p ?o ?g. }

• W3039660397 endingPage "1291.e1" @default.
• W3039660397 startingPage "1276" @default.
• W3039660397 abstract "Purpose Acetaminophen (APAP) has hepatotoxic potential when overdosed. Recent studies have reported serum alanine aminotransferase (ALT) elevations that resolve spontaneously with continued use of the drug, referred to as adaptation, in several individuals receiving therapeutic doses of APAP. However, the clinical significance of these ALT elevations remains unclear. This study was performed to investigate the incidence and characteristics of hepatic adaptation to therapeutic doses of APAP in healthy individuals. Methods In a randomized, single-blind, placebo-controlled study, 242 healthy Japanese individuals were enrolled. Each person received 3 g/d of APAP (n = 202) or placebo (n = 40) for 28 days. All study participants underwent analysis of genetic polymorphisms of CYP2E1 and UGT1A1; measurements of plasma APAP concentration and urine metabolites (glucuronide, sulfate, cysteine, and mercapturate); liver function monitoring, including ALT, microRNA-122, and high-mobility group box 1. Individuals with ALT levels remaining below the upper limit of normal (ULN; 40 U/L) during the study period were defined as tolerant and those with ALT elevations above the ULN as susceptible. Susceptible individuals who developed ALT elevations exceeding 2 × ULN discontinued use of the study drug for tolerability consideration. Susceptible individuals who had ALT elevations that decreased toward the ULN spontaneously with continued use of the study drug were classified as adaptation. Findings In the APAP group, 129 individuals (66%) were classified as tolerant and 65 (34%) as susceptible. Among 65 susceptible individuals, 12 (18%) discontinued use of APAP because of ALT elevations (>2 × ULN), whereas 53 (82%) completed 28-day APAP dosing. Thirty of 65 susceptible individuals (46%) had adaptation within 28 days. In the placebo group, no individuals was withdrawn from the study because of elevated ALT levels, 33 individuals (89%) were classified as tolerant, and 4 (11%) were classified as susceptible. None had clinical signs of liver injury. ALT level correlated significantly with microRNA-122 but not with high-mobility group box 1. No association was found between plasma APAP concentrations and ALT levels. Urinary excretion of APAP mercapturate was higher in susceptible than in tolerant individuals (P = 0.018, Wilcoxon or Kruskal-Wallis test). The frequency of homozygotes and compound heterozygotes for UGT1A1∗28 and UGT1A1∗6 (∗28/∗28, ∗6/∗6, and ∗6/∗28) was higher in susceptible than in tolerant individuals (13.9% vs 3.9%; P = 0.011, χ2 test). Implications These findings indicate that in healthy individuals, APAP at a therapeutic dose can cause transient and self-limiting ALT elevation, reflecting subclinical hepatocellular damage, and these ALT elevations may be associated with the disposition of APAP metabolites and genetic factors. UMIN-CTR identifier: UMIN000019607." @default.
• W3039660397 created "2020-07-10" @default.
• W3039660397 creator A5002931482 @default.
• W3039660397 creator A5013567557 @default.
• W3039660397 creator A5031155500 @default.
• W3039660397 creator A5039383162 @default.
• W3039660397 creator A5041063236 @default.
• W3039660397 creator A5048599186 @default.
• W3039660397 creator A5059069623 @default.
• W3039660397 creator A5059110173 @default.
• W3039660397 creator A5065216134 @default.
• W3039660397 creator A5074846489 @default.
• W3039660397 creator A5086840180 @default.
• W3039660397 date "2020-07-01" @default.
• W3039660397 modified "2023-10-11" @default.
• W3039660397 title "Hepatic Adaptation to Therapeutic Doses of Acetaminophen: An Exploratory Study in Healthy Individuals" @default.
• W3039660397 cites W1527821398 @default.
• W3039660397 cites W1875161015 @default.
• W3039660397 cites W1914476337 @default.
• W3039660397 cites W1967522801 @default.
• W3039660397 cites W1967684747 @default.
• W3039660397 cites W1967972402 @default.
• W3039660397 cites W1982728538 @default.
• W3039660397 cites W2000066924 @default.
• W3039660397 cites W2000837493 @default.
• W3039660397 cites W2005521037 @default.
• W3039660397 cites W2019826921 @default.
• W3039660397 cites W2029162899 @default.
• W3039660397 cites W2040361205 @default.
• W3039660397 cites W2044680278 @default.
• W3039660397 cites W2059655597 @default.
• W3039660397 cites W2060160079 @default.
• W3039660397 cites W2073530393 @default.
• W3039660397 cites W2093566822 @default.
• W3039660397 cites W2093982770 @default.
• W3039660397 cites W2095559659 @default.
• W3039660397 cites W2106551636 @default.
• W3039660397 cites W2111848990 @default.
• W3039660397 cites W2117807235 @default.
• W3039660397 cites W2122251157 @default.
• W3039660397 cites W2125284674 @default.
• W3039660397 cites W2139969518 @default.
• W3039660397 cites W2143053936 @default.
• W3039660397 cites W2143289568 @default.
• W3039660397 cites W2146196612 @default.
• W3039660397 cites W2146441593 @default.
• W3039660397 cites W2149212516 @default.
• W3039660397 cites W2150383835 @default.
• W3039660397 cites W2333160039 @default.
• W3039660397 cites W2339566661 @default.
• W3039660397 cites W2409425812 @default.
• W3039660397 cites W2550097095 @default.
• W3039660397 cites W2599336749 @default.
• W3039660397 cites W2732998799 @default.
• W3039660397 cites W2766458512 @default.
• W3039660397 cites W2793982710 @default.
• W3039660397 cites W4242966060 @default.
• W3039660397 doi "https://doi.org/10.1016/j.clinthera.2020.05.003" @default.
• W3039660397 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32620339" @default.
• W3039660397 hasPublicationYear "2020" @default.
• W3039660397 type Work @default.
• W3039660397 sameAs 3039660397 @default.
• W3039660397 citedByCount "5" @default.
• W3039660397 countsByYear W30396603972021 @default.
• W3039660397 countsByYear W30396603972022 @default.
• W3039660397 crossrefType "journal-article" @default.
• W3039660397 hasAuthorship W3039660397A5002931482 @default.
• W3039660397 hasAuthorship W3039660397A5013567557 @default.
• W3039660397 hasAuthorship W3039660397A5031155500 @default.
• W3039660397 hasAuthorship W3039660397A5039383162 @default.
• W3039660397 hasAuthorship W3039660397A5041063236 @default.
• W3039660397 hasAuthorship W3039660397A5048599186 @default.
• W3039660397 hasAuthorship W3039660397A5059069623 @default.
• W3039660397 hasAuthorship W3039660397A5059110173 @default.
• W3039660397 hasAuthorship W3039660397A5065216134 @default.
• W3039660397 hasAuthorship W3039660397A5074846489 @default.
• W3039660397 hasAuthorship W3039660397A5086840180 @default.
• W3039660397 hasConcept C120665830 @default.
• W3039660397 hasConcept C121332964 @default.
• W3039660397 hasConcept C126322002 @default.
• W3039660397 hasConcept C142724271 @default.
• W3039660397 hasConcept C197934379 @default.
• W3039660397 hasConcept C204787440 @default.
• W3039660397 hasConcept C27081682 @default.
• W3039660397 hasConcept C2777288759 @default.
• W3039660397 hasConcept C2778375690 @default.
• W3039660397 hasConcept C2778722691 @default.
• W3039660397 hasConcept C2992208098 @default.
• W3039660397 hasConcept C61511704 @default.
• W3039660397 hasConcept C71924100 @default.
• W3039660397 hasConcept C90924648 @default.
• W3039660397 hasConcept C98274493 @default.
• W3039660397 hasConceptScore W3039660397C120665830 @default.
• W3039660397 hasConceptScore W3039660397C121332964 @default.
• W3039660397 hasConceptScore W3039660397C126322002 @default.
• W3039660397 hasConceptScore W3039660397C142724271 @default.
• W3039660397 hasConceptScore W3039660397C197934379 @default.
• W3039660397 hasConceptScore W3039660397C204787440 @default.

• next